Shares of Healthcare Triangle (HCTI) jumped 8.4% to $0.77 on September 16 as investors revisited the company's plan to carve out its AI-powered customer engagement arm and list it independently on Nasdaq. No new announcement dropped today; the catalyst is continued digestion of a September 3 press release in which the board approved a stock dividend distributing a minority interest of Teyame AI Holdings shares to existing HCTI shareholders, alongside a signed separation agreement governing the planned split.
• Shareholders Would Get Free Shares — If Regulators Agree. The company has planned a direct listing of Teyame AI Holdings' common stock on Nasdaq. HCTI holders would receive a minority slice of the new entity's shares as a dividend, while the move "reflects a broader trend in healthcare technology companies seeking to unlock value in specialized AI assets." But completion is subject to SEC and Nasdaq approval — a process that could take months and carries no guarantee for a micro-cap with a turbulent compliance history.
• The Numbers Show Growth, Not Profits. HCTI reported Q2 2026 revenue of $9.19 million, up 158% year-over-year, with gross profit increasing 322% to $2.07 million. That top-line surge stems largely from folding in the Spain-based AI businesses, which reported roughly $32 million in revenue and $3.6 million in EBITDA for fiscal 2025. Yet over the trailing twelve months HCTI posted $13.9 million in revenue and negative $9.5 million in net losses, and operating cash flow was negative $16.5 million. Spinning off the most profitable piece raises an obvious question: what's left in the parent?
• The Market Cap Is Tiny, and Dilution Has Been Relentless. On July 24 the company issued 12.5 million new shares tied to legacy M&A deals, lifting the total to roughly 14.6 million shares outstanding.
The stock has declined approximately 99.9% over the past 52 weeks, ravaged by multiple reverse splits. At $0.77, the entire company is worth roughly $11 million — a fraction of the $50 million in consideration pledged for the original acquisition.
• A Direct Listing Skips the Cash Raise. Unlike an IPO, a direct listing lets existing shares trade without issuing new ones or raising fresh capital. The approach "suggests confidence in Teyame AI's market potential, but success hinges on regulatory approval and investor appetite" for a standalone AI play born from a micro-cap parent still burning cash. Until the SEC clears the registration statement, today's pop is speculation, not confirmation.